Eosinophil-activating Semiconducting Polymer Nanoparticles for Cancer Photo-immunotherapy
Angew Chem Int Ed Engl. 2024 May 3:e202405358. doi: 10.1002/anie.202405358. Online ahead of print.ABSTRACTEosinophils are important immune effector cells that affect T cell-mediated antitumor immunity. However, the low frequency and restrained activity of eosinophils restricted the development of cancer immunotherapies. We herein report an eosinophil-activating semiconducting polymer nanoparticle (SPNe) to improve photodynamic tumor immunogenicity, modulate eosinophil chemotaxis, and reinvigorate T-cell immunity for activated cancer photo-immunotherapy. SPNe is composed of an amphiphilic semiconducting polymer and a dipept...
Source: Angewandte Chemie - May 3, 2024 Category: Chemistry Authors: Chi Zhang Jingsheng Huang Mengke Xu Jie Yu Wei Xin Shasha He Kanyi Pu Source Type: research
Miniature mass spectrometer-based point-of-care assay for quantification of metformin and sitagliptin in human blood and urine
This study developed a point-of-care (POC) assay method utilizing a miniature mass spectrometer, enabling rapid and accurate quantification of MET and STG concentrations in human blood and urine. By combining the miniature mass spectrometer with paper spray ionization, this method simplifies the process into three to four steps, requires minimal amounts of bodily fluids (50 μL of blood and 2 μL of urine), and is able to obtain quantification results within approximately 2 min. Stable isotope-labeled internal standards were employed to enhance the accuracy and stability of measurement. The MS/MS responses exhibited good l...
Source: Analytical and Bioanalytical Chemistry - April 20, 2024 Category: Chemistry Authors: Jingying Chen Yaohan Li Jingjing Chen Ruimin Wang Miaoshan Lu Changbin Yu Source Type: research
Comprehensive safety profile of dipeptidyl peptidase-4 inhibitors: a post-marketing study based on FAERS database using signal detection algorithms
CONCLUSION: Several significant disproportionality signals were observed with DPP-4 inhibitors. However, clinicians have to consider the comorbidities and concomitant drugs while prescribing these drugs.PMID:38626310 | DOI:10.1080/14740338.2024.2343015 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - April 16, 2024 Category: Drugs & Pharmacology Authors: Dipika Bansal Beema T Yoosuf Muhammed Favas Kt Pinaki Dutta Source Type: research
A cross talk study on sitagliptin mediated reclamation on TGF β signalling, DPP 4, miR-29a and miR-24 expression in PCOS rats fed with high fat-high fructose diet
In conclusion, current results reflect the potential impact of STG against dyslipidaemia, inflammation and fibrosis in PCOS rats via regulating dyslipidaemia and fibrosis via DPP 4 mediated miR-29a expression.PMID:38604038 | DOI:10.1016/j.tice.2024.102375 (Source: Tissue and Cell)
Source: Tissue and Cell - April 11, 2024 Category: Cytology Authors: Dipti Nanda Anuradha Carani Venkatraman Kalpana Kalaivanan Source Type: research
A cross talk study on sitagliptin mediated reclamation on TGF β signalling, DPP 4, miR-29a and miR-24 expression in PCOS rats fed with high fat-high fructose diet
In conclusion, current results reflect the potential impact of STG against dyslipidaemia, inflammation and fibrosis in PCOS rats via regulating dyslipidaemia and fibrosis via DPP 4 mediated miR-29a expression.PMID:38604038 | DOI:10.1016/j.tice.2024.102375 (Source: Tissue and Cell)
Source: Tissue and Cell - April 11, 2024 Category: Cytology Authors: Dipti Nanda Anuradha Carani Venkatraman Kalpana Kalaivanan Source Type: research
Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients
This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes. A retrospective study was conducted in a tertiary centre among diabetic patients exposed to gliptins between the years 2008-2021. Data including demographics, comorbidities, medications, and laboratory results were collected using the MDClone platform. Seventy-six patients with type 2 diabetes treated with dipeptidyl-peptidase 4 inhibitors who subsequently developed bullous pemphigoid were compared with a cohort of 8,060 diabetic patients exposed to dipeptidyl-peptidase 4 inhibitors who did not develo...
Source: Acta Dermato-Venereologica - April 5, 2024 Category: Dermatology Authors: Dana Shalmon Efrat Bar-Ilan Alon Peled Shamir Geller Jonathan Bar Naama Schwartz Eli Sprecher Mor Pavlovsky Source Type: research
Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients
This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes. A retrospective study was conducted in a tertiary centre among diabetic patients exposed to gliptins between the years 2008-2021. Data including demographics, comorbidities, medications, and laboratory results were collected using the MDClone platform. Seventy-six patients with type 2 diabetes treated with dipeptidyl-peptidase 4 inhibitors who subsequently developed bullous pemphigoid were compared with a cohort of 8,060 diabetic patients exposed to dipeptidyl-peptidase 4 inhibitors who did not develo...
Source: Acta Derm Venereol A... - April 5, 2024 Category: Dermatology Authors: Dana Shalmon Efrat Bar-Ilan Alon Peled Shamir Geller Jonathan Bar Naama Schwartz Eli Sprecher Mor Pavlovsky Source Type: research
Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients
This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes. A retrospective study was conducted in a tertiary centre among diabetic patients exposed to gliptins between the years 2008-2021. Data including demographics, comorbidities, medications, and laboratory results were collected using the MDClone platform. Seventy-six patients with type 2 diabetes treated with dipeptidyl-peptidase 4 inhibitors who subsequently developed bullous pemphigoid were compared with a cohort of 8,060 diabetic patients exposed to dipeptidyl-peptidase 4 inhibitors who did not develo...
Source: Acta Dermato-Venereologica - April 5, 2024 Category: Dermatology Authors: Dana Shalmon Efrat Bar-Ilan Alon Peled Shamir Geller Jonathan Bar Naama Schwartz Eli Sprecher Mor Pavlovsky Source Type: research
Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients
This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes. A retrospective study was conducted in a tertiary centre among diabetic patients exposed to gliptins between the years 2008-2021. Data including demographics, comorbidities, medications, and laboratory results were collected using the MDClone platform. Seventy-six patients with type 2 diabetes treated with dipeptidyl-peptidase 4 inhibitors who subsequently developed bullous pemphigoid were compared with a cohort of 8,060 diabetic patients exposed to dipeptidyl-peptidase 4 inhibitors who did not develo...
Source: Acta Derm Venereol A... - April 5, 2024 Category: Dermatology Authors: Dana Shalmon Efrat Bar-Ilan Alon Peled Shamir Geller Jonathan Bar Naama Schwartz Eli Sprecher Mor Pavlovsky Source Type: research
Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients
This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes. A retrospective study was conducted in a tertiary centre among diabetic patients exposed to gliptins between the years 2008-2021. Data including demographics, comorbidities, medications, and laboratory results were collected using the MDClone platform. Seventy-six patients with type 2 diabetes treated with dipeptidyl-peptidase 4 inhibitors who subsequently developed bullous pemphigoid were compared with a cohort of 8,060 diabetic patients exposed to dipeptidyl-peptidase 4 inhibitors who did not develo...
Source: Acta Dermato-Venereologica - April 5, 2024 Category: Dermatology Authors: Dana Shalmon Efrat Bar-Ilan Alon Peled Shamir Geller Jonathan Bar Naama Schwartz Eli Sprecher Mor Pavlovsky Source Type: research
Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients
This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes. A retrospective study was conducted in a tertiary centre among diabetic patients exposed to gliptins between the years 2008-2021. Data including demographics, comorbidities, medications, and laboratory results were collected using the MDClone platform. Seventy-six patients with type 2 diabetes treated with dipeptidyl-peptidase 4 inhibitors who subsequently developed bullous pemphigoid were compared with a cohort of 8,060 diabetic patients exposed to dipeptidyl-peptidase 4 inhibitors who did not develo...
Source: Acta Derm Venereol A... - April 5, 2024 Category: Dermatology Authors: Dana Shalmon Efrat Bar-Ilan Alon Peled Shamir Geller Jonathan Bar Naama Schwartz Eli Sprecher Mor Pavlovsky Source Type: research
Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients
This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes. A retrospective study was conducted in a tertiary centre among diabetic patients exposed to gliptins between the years 2008-2021. Data including demographics, comorbidities, medications, and laboratory results were collected using the MDClone platform. Seventy-six patients with type 2 diabetes treated with dipeptidyl-peptidase 4 inhibitors who subsequently developed bullous pemphigoid were compared with a cohort of 8,060 diabetic patients exposed to dipeptidyl-peptidase 4 inhibitors who did not develo...
Source: Acta Dermato-Venereologica - April 5, 2024 Category: Dermatology Authors: Dana Shalmon Efrat Bar-Ilan Alon Peled Shamir Geller Jonathan Bar Naama Schwartz Eli Sprecher Mor Pavlovsky Source Type: research
Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients
This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes. A retrospective study was conducted in a tertiary centre among diabetic patients exposed to gliptins between the years 2008-2021. Data including demographics, comorbidities, medications, and laboratory results were collected using the MDClone platform. Seventy-six patients with type 2 diabetes treated with dipeptidyl-peptidase 4 inhibitors who subsequently developed bullous pemphigoid were compared with a cohort of 8,060 diabetic patients exposed to dipeptidyl-peptidase 4 inhibitors who did not develo...
Source: Acta Derm Venereol A... - April 5, 2024 Category: Dermatology Authors: Dana Shalmon Efrat Bar-Ilan Alon Peled Shamir Geller Jonathan Bar Naama Schwartz Eli Sprecher Mor Pavlovsky Source Type: research
The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China
To estimate the long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin as an add-on therapy for type 2 diabetes patients inadequately controlled on metformin in China, to better inform heal... (Source: Health Economics Review)
Source: Health Economics Review - April 2, 2024 Category: Health Management Authors: Shuyan Gu, Jinghong Gu, Xiaoyong Wang, Xiaoling Wang, Lu Li, Hai Gu and Biao Xu Tags: Research Source Type: research
The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China
ConclusionOnce-weekly semaglutide may represent a cost-effective add-on therapy alternative to sitagliptin for type 2 diabetes patients inadequately controlled on metformin in China. (Source: Health Economics Review)
Source: Health Economics Review - April 2, 2024 Category: International Medicine & Public Health Source Type: research
